Companies › NEUP

NEUPHORIA THERAPEUTICS IN (NEUP)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001191070 · EDGAR filings · Updated 2026-07-28

NEUPHORIA THERAPEUTICS IN (NEUP) has reported institutional ownership of 32.5%, with 19 institutional managers holding positions valued at $7.15M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (3)

• 2026-07-28 — SCHEDULE 13G/A filed
• 2026-07-24 — DEFA14A filed
• 2026-07-24 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-05-26 — Current report (8-K) filed
• 2026-05-15 — Quarterly report (10-Q) filed
• 2026-02-17 — Quarterly report (10-Q) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NEUPHORIA THERAPEUTICS IN has 19 institutional holders and institutional ownership of 32.5%.

Insider activity

Insiders reported 1 transactions (1 buys, 0 sells) across 1 reporting insiders, with a net reported value of $3.29M.

Data flags from SEC filings

Related companies

CINGULATE INC (CING) · BioXcel Therapeutics Inc (BTAI) · Koninklijke Philips NV (PHG) · Kyntra Bio Inc (KYNB) · CERVOMED INC (CRVO) · TEVOGEN BIO HOLDINGS INC (TVGN)